feedzop-word-mark-logo
searchLogin
Feedzop
homeFor YouIndiaIndia
You
bookmarksYour BookmarkshashtagYour Topics
Trending
trending

PM-KISAN 21st installment release

trending

Rajasthan University result declared

trending

Babar Azam ends century drought

trending

Messi scores against Angola

trending

President Murmu interacts with students

trending

Srinagar police station explosion

trending

Shraddha Kapoor drug party probe

trending

Spain focuses World Cup qualification

trending

Maruti Suzuki Grand Vitara recall

Terms of UsePrivacy PolicyAboutJobsPartner With Us

© 2025 Advergame Technologies Pvt. Ltd. ("ATPL"). Gamezop ® & Quizzop ® are registered trademarks of ATPL.

Gamezop is a plug-and-play gaming platform that any app or website can integrate to bring casual gaming for its users. Gamezop also operates Quizzop, a quizzing platform, that digital products can add as a trivia section.

Over 5,000 products from more than 70 countries have integrated Gamezop and Quizzop. These include Amazon, Samsung Internet, Snap, Tata Play, AccuWeather, Paytm, Gulf News, and Branch.

Games and trivia increase user engagement significantly within all kinds of apps and websites, besides opening a new stream of advertising revenue. Gamezop and Quizzop take 30 minutes to integrate and can be used for free: both by the products integrating them and end users

Increase ad revenue and engagement on your app / website with games, quizzes, astrology, and cricket content. Visit: business.gamezop.com

Property Code: 5571

Home / Health / Bondi Sands Sunscreens Recalled for Inadequate UV Protection

Bondi Sands Sunscreens Recalled for Inadequate UV Protection

14 Nov

•

Summary

  • Bondi Sands recalls two sunscreen products due to texture issues
  • Concerns that products may not provide adequate sun protection
  • Customers advised to return affected batches for refund or replacement
Bondi Sands Sunscreens Recalled for Inadequate UV Protection

On November 11, 2025, the Therapeutic Goods Administration (TGA) announced that Australian skincare brand Bondi Sands has recalled two of its sunscreen products. The affected products are the Bondi Sands Zinc Mineral Broad Spectrum UVA & UVB Protection Sunscreen SPF 50+ Face Lotion (60ml) and the Body Lotion (120ml).

The TGA stated that some of the products may have an "uneven texture" and "visible water separating out of the product," which could affect the Sun Protection Factor (SPF) rating and overall performance of the sunscreens. This means the ingredients are no longer properly mixed, potentially leading to inadequate sun protection for users.

Bondi Sands has advised customers who have purchased the affected batches, which are listed by the TGA, to return the products to the place of purchase for a replacement or full refund. The company has expressed regret for any inconvenience caused to its customers.

This recall comes just months after another sunscreen brand, Ultra Violette, had to pull its Lean Screen SPF Mattifying Zinc Sunscreen from shelves following alarming test results from Australia's consumer watchdog. The TGA has also named 20 additional sunscreens that contain the same base formula as the Ultra Violette product.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
Bondi Sands has recalled its Zinc Mineral Broad Spectrum UVA & UVB Protection Sunscreen SPF 50+ Face Lotion (60ml) and Body Lotion (120ml) due to concerns about inadequate sun protection.
The Therapeutic Goods Administration (TGA) found that some of the Bondi Sands sunscreen products had an uneven texture and visible water separation, which could affect the Sun Protection Factor (SPF) rating and overall performance of the sunscreens.
Customers who have purchased the affected batches of Bondi Sands sunscreens are advised to return the products to the place of purchase for a replacement or full refund, or contact the company directly.

Read more news on

Healthside-arrowAustraliaside-arrow

You may also like

Biocon Cuts Biosimilar Costs by 50% as US Eases Testing Rules

1 day ago • 7 reads

article image

Ariceum's Radioligand Therapy Enters Trials for Rare, Aggressive Cancers

12 Nov • 7 reads

article image

BioCryst Acquires Astria, Analysts Adjust Price Target

13 Nov • 15 reads

article image

Mayo Clinic's Stem Cell Patch Aims to Revolutionize Heart Failure Treatment

10 Nov • 37 reads

Contaminated Baby Formula Hospitalizes Infants Nationwide

10 Nov • 36 reads

article image